Tezepelumab Tested in Adults With Moderate to Very Severe COPD
Tests tezepelumab against placebo in adults aged 40 to 80 with COPD.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Key facts
- Where
- Ferrara, Florence, Montebelluna, Naples, Pavia, Rome, Sassari, Telese Terme, and Tradate, ItalySee the 9 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06883305, who can take part
Where in Italy
- University Hospital Of FerraraFerrara, ItalyNo longer taking part
- Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyNo longer taking part
- Azienda Unita' Locale Socio Sanitaria N. 2 Marca TrevigianaMontebelluna, ItalyNo longer taking part
- Azienda Ospedaliera dei ColliNaples, ItalyNo longer taking part
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyNo longer taking part
- Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata FonRome, ItalyNo longer taking part
- Azienda Ospedaliero-Universitaria di SassariSassari, ItalyNo longer taking part
- Istituti Clinici Scientifici Maugeri S.p.A. Societa' Benefit In Forma Abbreviata Istituti Clinici Scientifici Maugeri S.p.A. Sb O Anche Ics Maugeri S.p.A. Sb O Maugeri S.p.A. SbTelese Terme, ItalyNo longer taking part
- Istituti Clinici Scientifici Maugeri S.p.A. Societa' Benefit In Forma Abbreviata Istituti Clinici Scientifici Maugeri S.p.A. Sb O Anche Ics Maugeri S.p.A. Sb O Maugeri S.p.A. SbTradate, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06883305EU 2024-517458-90-00
- Record updated
- 3 September 2026
- Original description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)Read full original descriptionShow less
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Inclusion: ≥40 to ≤80 years old; COPD diagnosis ≥1 year,; Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC <0.70 at screening; Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1; ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy; EOS ≥ 150 cells/μL during screening; CAT ≥15 at screening; Former or current smokers ≥10 pack-years.
Exclusion: Tuberculosis requiring treatment within 12 months prior V2; Malignancies current or past; Concomitant therapies:; Macrolides (less than 6 months); Systemic immuno-suppressive, -modulating medications; Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD; Any unstable disorder that can impact participants safety or study outcomes; Asthma, incl. pediatric, or ACOS; LTOT >4.0 L/min or O2 saturation <89% despite LTOT.